These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 27659287

  • 21. Specific inhibition of HCN channels slows rhythm differently in atria, ventricle and outflow tract and stabilizes conduction in the anoxic-reoxygenated embryonic heart model.
    Sarre A, Pedretti S, Gardier S, Raddatz E.
    Pharmacol Res; 2010 Jan; 61(1):85-91. PubMed ID: 19818405
    [Abstract] [Full Text] [Related]

  • 22. The biological effects of ivabradine in cardiovascular disease.
    Speranza L, Franceschelli S, Riccioni G.
    Molecules; 2012 Apr 30; 17(5):4924-35. PubMed ID: 22547315
    [Abstract] [Full Text] [Related]

  • 23. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, Ford I, SHIFT Investigators.
    J Am Coll Cardiol; 2012 May 29; 59(22):1938-45. PubMed ID: 22617188
    [Abstract] [Full Text] [Related]

  • 24. Ivabradine in acute coronary syndromes: Protection beyond heart rate lowering.
    Niccoli G, Borovac JA, Vetrugno V, Camici PG, Crea F.
    Int J Cardiol; 2017 Jun 01; 236():107-112. PubMed ID: 28256323
    [Abstract] [Full Text] [Related]

  • 25. Analysis of variants in the HCN4 gene and in three single nucleotide polymorphisms of the CYP3A4 gene for association with ivabradine reduction in heart rate: A preliminary report.
    Núñez L, Crespo-Leiro MG, Marrón-Liñares GM, Suarez-Fuentetaja N, Barge-Caballero E, Paniagua-Martín MJ, Marzoa-Rivas R, Grille-Cancela Z, Muñiz-García J, Vazquez-Rodriguez JM, Hermida-Prieto M.
    Cardiol J; 2016 Jun 01; 23(5):573-582. PubMed ID: 27439367
    [Abstract] [Full Text] [Related]

  • 26. I(f) inhibition in cardiovascular diseases.
    Thollon C, Vilaine JP.
    Adv Pharmacol; 2010 Jun 01; 59():53-92. PubMed ID: 20933199
    [Abstract] [Full Text] [Related]

  • 27. Cardioprotective effects of the Ιf current inhibition by ivabradine during cardiac dysfunction.
    Su JB.
    Curr Pharm Biotechnol; 2014 Jun 01; 14(14):1213-9. PubMed ID: 24831809
    [Abstract] [Full Text] [Related]

  • 28. Role of the Funny Current Inhibitor Ivabradine in Cardiac Pharmacotherapy: A Systematic Review.
    Petite SE, Bishop BM, Mauro VF.
    Am J Ther; 2018 Jun 01; 25(2):e247-e266. PubMed ID: 26910057
    [Abstract] [Full Text] [Related]

  • 29. Addition of ivabradine to betablockers in patients with atrial fibrillation: Effects on heart rate and exercise tolerance.
    Caminiti G, Fossati C, Rosano G, Volterrani M.
    Int J Cardiol; 2016 Jan 01; 202():73-4. PubMed ID: 26386926
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor.
    Borer JS, Le Heuzey JY.
    Am J Ther; 2008 Jan 01; 15(5):461-73. PubMed ID: 18806523
    [Abstract] [Full Text] [Related]

  • 32. Review of the If selective channel inhibitor ivabradine in the treatment of chronic stable angina.
    Prasad UK, Gray D, Purcell H.
    Adv Ther; 2009 Feb 01; 26(2):127-37. PubMed ID: 19259630
    [Abstract] [Full Text] [Related]

  • 33. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT.
    Voors AA, van Veldhuisen DJ, Robertson M, Ford I, Borer JS, Böhm M, Komajda M, Swedberg K, Tavazzi L, SHIFT investigators.
    Eur J Heart Fail; 2014 Apr 01; 16(4):426-34. PubMed ID: 24504937
    [Abstract] [Full Text] [Related]

  • 34. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
    Majewski S, Slomka S, Zielinska-Wyderkiewicz E, Ciebiada M, Gorski P.
    Am J Cardiovasc Drugs; 2012 Jun 01; 12(3):179-88. PubMed ID: 22409211
    [Abstract] [Full Text] [Related]

  • 35. Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression.
    Suffredini S, Stillitano F, Comini L, Bouly M, Brogioni S, Ceconi C, Ferrari R, Mugelli A, Cerbai E.
    Br J Pharmacol; 2012 Mar 01; 165(5):1457-66. PubMed ID: 21838751
    [Abstract] [Full Text] [Related]

  • 36. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology.
    Camm AJ, Lau CP.
    Drugs R D; 2003 Mar 01; 4(2):83-9. PubMed ID: 12718562
    [Abstract] [Full Text] [Related]

  • 37. Acute ivabradine treatment reduces heart rate without increasing atrial fibrillation inducibility irrespective of underlying vagal activity in dogs.
    Uemura K, Inagaki M, Zheng C, Kawada T, Li M, Fukumitsu M, Sugimachi M.
    Heart Vessels; 2017 Apr 01; 32(4):484-494. PubMed ID: 27844147
    [Abstract] [Full Text] [Related]

  • 38. Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure.
    Cavusoglu Y, Mert U, Nadir A, Mutlu F, Morrad B, Ulus T.
    J Cardiovasc Med (Hagerstown); 2015 Sep 01; 16(9):603-9. PubMed ID: 24922198
    [Abstract] [Full Text] [Related]

  • 39. Update on ivabradine for heart failure.
    Borer JS, Tavazzi L.
    Trends Cardiovasc Med; 2016 Jul 01; 26(5):444-9. PubMed ID: 26934996
    [Abstract] [Full Text] [Related]

  • 40. Ivabradine for rate control in atrial fibrillation.
    Kosiuk J, Oebel S, John S, Hilbert S, Hindricks G, Bollmann A.
    Int J Cardiol; 2015 Jan 20; 179():27-8. PubMed ID: 25464400
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.